Newborn screening (NBS) — testing all newborns for a panel of metabolic, endocrine, hematological, and hearing disorders before symptoms develop — is one of the most successful public health programs in U.S. history. Since PKU screening began in the 1960s, newborn screening has prevented tens of thousands of cases of intellectual disability, metabolic crises, and premature death from treatable conditions. The Recommended Uniform Screening Panel (RUSP) — maintained by HHS — currently includes 37 core conditions and 26 secondary conditions, with state-specific panels varying around this minimum. Our pediatric supply catalog and laboratory supplies section support neonatal care and screening programs.
The Newborn Screening Process
Universal NBS requires a dried blood spot (DBS) collected from a heel stick at 24–48 hours of life, ideally after adequate formula or breast milk intake to ensure metabolite levels are representative. Early collection (<24 hours) before adequate feeding may produce false-negative results for conditions like PKU where phenylalanine accumulates from protein intake. The DBS card (Guthrie card) is dried, stored, and shipped to the state public health laboratory for multiplex testing using tandem mass spectrometry (MS/MS — capable of detecting 40+ metabolic conditions simultaneously from a single blood spot), immunoassays (congenital hypothyroidism, congenital adrenal hyperplasia, galactosemia), and DNA-based methods (SCID, SMA). Heel stick supplies including lancets, Guthrie DBS collection cards, warming packs, and glucose screening strips for neonatal hypoglycemia are available in our pediatric and lab supplies sections.
Expanding the Panel: SMA and SCID
Recent additions to the RUSP demonstrate the expanding scope of NBS: Spinal muscular atrophy (SMA) was added in 2018 — SMN1 gene deletion detection by PCR identifies SMA before symptom onset, enabling treatment with nusinersen or onasemnogene abeparvovec (Zolgensma gene therapy) before irreversible motor neuron loss. SCID (severe combined immunodeficiency) was added in 2010 — TREC (T-cell receptor excision circle) quantification identifies T-cell lymphopenia before infections occur, enabling hematopoietic stem cell transplantation with >90% cure rates when performed before infection vs 40–60% after. These conditions illustrate the principle that NBS value depends on effective treatment being available — the rapid expansion of gene therapies for genetic diseases is continuously expanding the conditions where early NBS detection translates to dramatically improved outcomes.
